Everything You Need to Know About Retatrutide: The 2026 Triple-Agonist Frontier
Clinical Status: Phase 3 Investigational Compound (TRIUMPH Trials) Mechanism: GIP / GLP-1 / Glucagon Triple Receptor Agonist Last Updated: April 25, 2026 As we move through 2026, the landscape of medical weight loss and metabolic health is shifting from “dual-action” treatments like Tirzepatide to the next generation: Retatrutide. Often referred to as “The Triple G,” […]